SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?

SCLC is an aggressive, malignant neuroendocrine cancer that is diagnosed at the incurable extensive stage in more than 60% of patients. The incorporation of antibodies blocking immune-suppressive signaling through programmed death-1 (PD-1) pathway resulted in modest survival improvement and represents an important therapeutic advance in extensive-stage SCLC.1,2 The limited options of effective therapy for relapsed SCLC supported the reintroduction of the same frontline cytotoxic chemotherapy as salvage treatment.